Scandion Oncology is now on Nasdaq First North Growth Market

SCO-101 is currently being tested in clinical trials with colorectal and pancreatic cancer patients

Overcoming chemotherapy resistance

Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.

Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.

Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.

Events

Upcoming events Past events All

10. Nov 20

InvestorUgen hos Dansk Aktionærforening

Bo Rode Hansen presented at InvestorUgen at Dansk Aktionærforening

Watch

20. Nov 20

Scandion Oncology webcast

Scandion Oncology presented highlights from Q3, 2020

See presentation

24. Nov 20

Aktieportfölje Live

Bo Rode Hansen has presented at Aktieportföljen Live.

Watch

25. Nov 20

Life Science Investor Konference

Company update by CEO Bo Rode Hansen.

Watch

02. Dec 20

BioStock Live med Scandion Oncology

BioStock Studio: Scandion Oncology outlines vision to fight cancer drug resistance

Watch

02. Dec 20

Nordnet Live

Scandion Oncology presentation by CEO Bo Rode Hansen

Watch

07. Dec 20

Ophelia Invest Talks

Bliv klogere på biotek branchen og særligt på biotekselskabet Scandion Oncology.

Listen (podcast)

08. Dec 20

MVA Oncology Network

Jan Stenvang presented at MVA Oncology Network Meeting. See presentation.

Watch recording

09. Dec 20

San Antonio Breast Cancer Symposium

Jan Stenvang presented a poster.

See poster

11. Jan 21

Biotech Showcase. Jan 11-15, 2021

Meet President & CEO, Bo Rode Hansen, at Biotech Showcase

10. Feb 21

Swiss Nordic Bio

Meet President & CEO, Bo Rode Hansen, at Swiss Nordic.

19. Feb 21

Live webcast

Invitation to Scandion Oncology A/S live webcast on February 19, 2021

21. Apr 21

Bo Rode Hansen at Økonomisk Ugebrev

Watch President & CEO Bo Rode Hansen’s presentation at Økonomisk Ugebrev.

Watch

11. May 21

Nordnet / Proinvestor / HC Andersen Capital Biotech Event

Invitation to live (virtual) event on May 11 at 10.00 a.m.

Pipeline

Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance.

Clinical Trials

Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Investors

Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.

We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.

Overcoming chemotherapy resistance

Events

Stay updated with our newsletter

Pipeline

Clinical Trials

Investors